Intriguingly, both canonical and noncanonical Wnt signaling pathways are activated in tamoxifen-resistant breast cancer cells, and Wnt3a increases the resistance of EsR+ breast cancer cells to tamoxifen treatment [384]. The gene discussed is WNT3A; the disease is breast cancer.